Ratings by Truist Securities (Srikripa Devarakonda)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/3/2026 | Scholar Rock | SRRK | Maintain | Buy (N/A) |
|
Details | ||
| 2/19/2026 | Madrigal Pharmaceuticals | MDGL | Maintain | Buy (N/A) |
|
Details | ||
| 2/10/2026 | Incyte | INCY | Maintain | Hold (N/A) |
|
Details | ||
| 2/5/2026 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 2/5/2026 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 2/4/2026 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 2/3/2026 | Cytokinetics | CYTK | Maintain | Buy (N/A) |
|
Details | ||
| 1/27/2026 | Cytokinetics | CYTK | Maintain | Buy (N/A) |
|
Details | ||
| 1/12/2026 | Madrigal Pharmaceuticals | MDGL | Maintain | Buy (N/A) |
|
Details | ||
| 1/5/2026 | Protagonist Therapeutics | PTGX | Maintain | Buy (N/A) |
|
Details | ||
| 12/23/2025 | Incyte | INCY | Maintain | Hold (N/A) |
|
Details | ||
| 12/22/2025 | Cytokinetics | CYTK | Maintain | Buy (N/A) |
|
Details | ||
| 12/15/2025 | Septerna Inc | SEPN | New Coverage | Buy (N/A) |
25.44 (28.78) |
13.13% | Details | |
| 12/12/2025 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 12/9/2025 | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
|
Details | ||
| 12/3/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (N/A) |
|
Details | ||
| 11/25/2025 | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
|
Details | ||
| 11/19/2025 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 11/3/2025 | Edgewise Therapeutics | EWTX | Maintain | Buy (N/A) |
|
Details | ||
| 10/30/2025 | Nurix | NRIX | Maintain | Buy (N/A) |
|
Details | ||
| 10/30/2025 | Nurix | NRIX | Maintain | Buy (N/A) |
|
Details | ||
| 10/29/2025 | Incyte | INCY | Maintain | Hold (N/A) |
|
Details | ||
| 10/28/2025 | Protagonist Therapeutics | PTGX | Maintain | Buy (N/A) |
|
Details | ||
| 10/20/2025 | Scholar Rock | SRRK | Maintain | Buy (N/A) |
|
Details | ||
| 10/14/2025 | Scholar Rock | SRRK | Maintain | Buy (N/A) |
|
Details | ||
| 9/30/2025 | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
|
Details | ||
| 9/24/2025 | Scholar Rock | SRRK | Maintain | Buy (N/A) |
|
Details | ||
| 9/9/2025 | Tourmaline Bio | TRML | Downgrade | Hold (Buy) |
30.18 (47.98) |
58.98% | Details | |
| 9/2/2025 | Cytokinetics | CYTK | Maintain | Buy (N/A) |
|
Details | ||
| 8/11/2025 | Regeneron Pharma | REGN | Maintain | Buy (N/A) |
|
Details | ||
| 8/8/2025 | Arvinas Inc. | ARVN | Maintain | (N/A) |
|
Details | ||
| 7/29/2025 | Incyte | INCY | Maintain | Hold (N/A) |
|
Details | ||
| 7/18/2025 | Scholar Rock | SRRK | Maintain | Buy (N/A) |
|
Details | ||
| 6/26/2025 | Scholar Rock | SRRK | Maintain | Buy (N/A) |
|
Details | ||
| 6/24/2025 | Amgen | AMGN | Maintain | Hold (N/A) |
|
Details | ||
| 6/23/2025 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 6/2/2025 | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
|
Details | ||
| 6/2/2025 | Regeneron Pharma | REGN | Maintain | Buy (N/A) |
|
Details | ||
| 5/27/2025 | Incyte | INCY | Maintain | Hold (N/A) |
|
Details | ||
| 5/21/2025 | Tourmaline Bio | TRML | Maintain | Buy (N/A) |
|
Details | ||
| 5/16/2025 | AbCellera Biologics | ABCL | Maintain | Buy (N/A) |
|
Details | ||
| 5/12/2025 | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
|
Details | ||
| 5/9/2025 | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
|
Details | ||
| 5/5/2025 | Arvinas Inc. | ARVN | Downgrade | Hold (Buy) |
7.23 (13.60) |
88.11% | Details | |
| 4/29/2025 | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
|
Details | ||
| 4/29/2025 | Repligen | RGEN | Maintain | Buy (N/A) |
|
Details | ||
| 4/28/2025 | Scholar Rock | SRRK | Maintain | Buy (N/A) |
|
Details | ||
| 4/23/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (N/A) |
|
Details | ||
| 4/10/2025 | Tourmaline Bio | TRML | Maintain | Buy (N/A) |
|
Details | ||
| 4/9/2025 | Keros Therapeutics | KROS | Maintain | Buy (N/A) |
|
Details | ||
| 4/2/2025 | Edgewise Therapeutics | EWTX | Maintain | Buy (N/A) |
|
Details | ||
| 3/25/2025 | Scholar Rock | SRRK | Maintain | Buy (N/A) |
|
Details | ||
| 3/21/2025 | Edgewise Therapeutics | EWTX | Maintain | Buy (N/A) |
|
Details | ||
| 3/18/2025 | Incyte | INCY | Maintain | Hold (N/A) |
|
Details | ||
| 3/10/2025 | Protagonist Therapeutics | PTGX | Maintain | Buy (N/A) |
|
Details | ||
| 3/3/2025 | Protagonist Therapeutics | PTGX | Maintain | Buy (N/A) |
|
Details | ||
| 2/28/2025 | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
|
Details | ||
| 2/27/2025 | Tourmaline Bio | TRML | Maintain | Buy (N/A) |
|
Details | ||
| 2/25/2025 | Scholar Rock | SRRK | Maintain | Buy (N/A) |
|
Details | ||
| 2/7/2025 | Protagonist Therapeutics | PTGX | Maintain | Buy (N/A) |
|
Details | ||
| 2/5/2025 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 2/3/2025 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 2/3/2025 | Abbvie | ABBV | Maintain | Buy (N/A) |
|
Details | ||
| 1/8/2025 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 1/8/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (N/A) |
|
Details | ||
| 1/8/2025 | Abbvie | ABBV | Maintain | Buy (N/A) |
|
Details | ||
| 12/23/2024 | Keros Therapeutics | KROS | Maintain | Buy (N/A) |
|
Details | ||
| 12/17/2024 | Affimed Therapeutics | AFMD | Maintain | Buy (Buy) |
|
Details | ||
| 12/16/2024 | Edgewise Therapeutics | EWTX | Maintain | Buy (N/A) |
|
Details | ||
| 12/5/2024 | Edgewise Therapeutics | EWTX | Maintain | Buy (Buy) |
|
Details | ||
| 11/27/2024 | Edgewise Therapeutics | EWTX | Maintain | Buy (N/A) |
|
Details | ||
| 11/25/2024 | Scholar Rock | SRRK | Maintain | Buy (N/A) |
|
Details | ||
| 11/22/2024 | Protagonist Therapeutics | PTGX | Maintain | Buy (N/A) |
|
Details | ||
| 11/5/2024 | Keros Therapeutics | KROS | Maintain | Buy (Buy) |
|
Details | ||
| 11/1/2024 | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
|
Details | ||
| 10/17/2024 | Verastem | VSTM | Maintain | Buy (Buy) |
|
Details | ||
| 10/17/2024 | Cytokinetics | CYTK | Maintain | Buy (Buy) |
|
Details | ||
| 10/16/2024 | Scholar Rock | SRRK | Maintain | Buy (Buy) |
|
Details | ||
| 10/7/2024 | Scholar Rock | SRRK | Maintain | Buy (N/A) |
|
Details | ||
| 10/1/2024 | Nurix | NRIX | Maintain | Buy (N/A) |
|
Details | ||
| 9/27/2024 | Biomea Fusion Inc. | BMEA | Upgrade | Buy (Hold) |
8.77 (1.39) |
-84.15% | Details | |
| 9/19/2024 | Edgewise Therapeutics | EWTX | Maintain | Buy (N/A) |
|
Details | ||
| 9/18/2024 | Incyte | INCY | Downgrade | Hold (Buy) |
66.43 (95.94) |
44.42% | Details | |
| 9/17/2024 | Affimed Therapeutics | AFMD | Maintain | Buy (N/A) |
|
Details | ||
| 9/11/2024 | Tourmaline Bio | TRML | Maintain | Buy (Buy) |
|
Details | ||
| 9/9/2024 | Protagonist Therapeutics | PTGX | New Coverage | Buy (N/A) |
41.50 (92.09) |
121.9% | Details | |
| 8/13/2024 | Verastem | VSTM | Maintain | Buy (N/A) |
|
Details | ||
| 7/31/2024 | Nurix | NRIX | New Coverage | Buy (N/A) |
20.77 (15.10) |
-27.3% | Details | |
| 7/8/2024 | Verastem | VSTM | Maintain | Buy (N/A) |
|
Details | ||
| 6/11/2024 | Biomea Fusion Inc. | BMEA | Downgrade | Hold (Buy) |
4.14 (8.77) |
111.84% | Details | |
| 5/29/2024 | Cytokinetics | CYTK | Maintain | Buy (N/A) |
|
Details | ||
| 4/30/2024 | Incyte | INCY | Maintain | Buy (N/A) |
|
Details | ||
| 4/17/2024 | Tourmaline Bio | TRML | Maintain | Buy (N/A) |
|
Details | ||
| 3/1/2024 | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
|
Details | ||
| 2/14/2024 | Incyte | INCY | Maintain | Buy (N/A) |
|
Details | ||
| 12/27/2023 | Cytokinetics | CYTK | Maintain | Buy (N/A) |
|
Details | ||
| 12/27/2023 | Cytokinetics | CYTK | Maintain | Buy (N/A) |
|
Details | ||
| 11/15/2023 | Verastem | VSTM | Maintain | Buy (N/A) |
|
Details | ||
| 11/3/2023 | Kymera Therapeutics | KYMR | Maintain | Buy (N/A) |
|
Details | ||
| 8/11/2023 | Affimed Therapeutics | AFMD | Maintain | Buy (N/A) |
|
Details | ||
| 8/2/2023 | Incyte | INCY | Maintain | Buy (N/A) |
|
Details | ||
| 7/11/2023 | Verastem | VSTM | Maintain | Buy (N/A) |
|
Details | ||
| 6/30/2023 | Kymera Therapeutics | KYMR | New Coverage | Buy (N/A) |
22.40 (83.49) |
272.72% | Details | |
| 5/1/2023 | Edgewise Therapeutics | EWTX | New Coverage | Buy (N/A) |
8.77 (27.82) |
217.22% | Details | |
| 3/20/2023 | 9 Meter Biopharma | NMTR | Downgrade | Hold (Buy) |
1.41 (0.07) |
-95.04% | Details | |
| 1/4/2023 | Keros Therapeutics | KROS | Maintain | Buy (N/A) |
|
Details | ||
| 12/20/2022 | Cytokinetics | CYTK | New Coverage | Buy (N/A) |
44.02 (60.41) |
37.23% | Details | |
| 11/21/2022 | Verastem | VSTM | Maintain | Buy (N/A) |
|
Details | ||
| 11/21/2022 | 9 Meter Biopharma | NMTR | Maintain | Buy (N/A) |
|
Details | ||
| 10/18/2022 | Keros Therapeutics | KROS | New Coverage | Buy (N/A) |
46.25 (11.30) |
-75.57% | Details | |
| 9/26/2022 | Verastem | VSTM | Maintain | Buy (N/A) |
|
Details | ||
| 8/2/2022 | Incyte | INCY | Maintain | Buy (N/A) |
|
Details | ||
| 7/12/2022 | Scholar Rock | SRRK | Maintain | Buy (N/A) |
|
Details | ||
| 3/9/2022 | Verastem | VSTM | New Coverage | Buy (N/A) |
1.12 (6.38) |
469.64% | Details | |
| 11/23/2021 | Affimed Therapeutics | AFMD | Maintain | Buy (N/A) |
|
Details | ||
| 10/21/2021 | Affimed Therapeutics | AFMD | New Coverage | Buy (N/A) |
6.07 (0.18) |
-97.03% | Details | |
| 6/3/2021 | Constellation Pharmaceuticals | CNST | Downgrade | Hold (Buy) |
33.57 (33.99) |
1.25% | Details | |
| 1/7/2021 | Incyte | INCY | New Coverage | Buy (N/A) |
84.31 (66.43) |
-21.21% | Details |
